GSK has been enjoying regulatory momentum in recent months as it works to bring its antibody-drug conjugate (ADC) Blenrep back to markets around the globe. | As GSK's Blenrep makes its return to ...

GSK (GSK) stock in focus as the FDA staff raise safety concerns over Blenrep combo for multiple myeloma ahead of an AdCom ...

The FDA evaluates glofitamab and daratumumab for lymphoma and myeloma treatments, highlighting trial demographics and ...

Capricor slumps 33% as the FDA rejects its BLA for DMD drug, deramiocel, citing lack of effectiveness data and CMC issues.

The company said it was optimistic that the issues identified by the Food and Drug Administration could be resolved with new data.

Detailed price information for Capricor Therap (CAPR-Q) from The Globe and Mail including charting and trades.

BrainStorm Cell Therapeutics issued a statement Tuesday supporting a Citizens’ Petition submitted to the FDA requesting the ...

BCLI READ THE FULL BCLI RESEARCH REPORT Business Update Citizen’s Petition Filed Requesting FDA Approve NurOwn™ On July 3, 2025, a Citizen’s Petition was filed with the U.S. Food and Drug ...

The US Food and Drug Administration (FDA) convenes public advisory committee meetings to address issues in new drug applications (NDAs), biologics license applications (BLAs), or clinical trials ...

Capricor's DMD therapy Deramiocel is under FDA Priority Review with no major issues flagged; PDUFA date set for August 31, 2025.

Detailed price information for Capricor Therap (CAPR-Q) from The Globe and Mail including charting and trades.